Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...
Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
* Top-line results from approximately 27,500-patient event-driven fourier study are anticipated in q1 of 2017 Sign up here. * Amgen Inc - "effect of repatha on cardiovascular morbidity and mortality ...
Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback